
An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in China
Xinyi Yang, Congran Li, Xiukun Wang, Zhonghui Zheng, Peiyi Sun, Chunjie Xu, Luni Chen, Jiandong Jiang, Staffan Normark, Birgitta Henriques-Normark, Xuefu You
An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in China
Antibacterial resistance is a global health threat that requires further concrete action on the part of all countries. In this context, one of the biggest concerns is whether enough new antibacterial drugs are being discovered and developed. Although several high-quality reviews on clinical antibacterial drug pipelines from a global perspective were published recently, none provides comprehensive information on original antibacterial drugs at clinical stages in China. In this review, we summarize the latest progress of novel antibacterial drugs approved for marketing and under clinical evaluation in China since 2019. Information was obtained by consulting official websites, searching commercial databases, retrieving literature, asking personnel from institutions or companies, and other means, and a considerable part of the data covered here has not been included in other reviews. As of June 30, 2023, a total of 20 antibacterial projects from 17 Chinese pharmaceutical companies or developers were identified and updated. Among them, two new antibacterial drugs that belong to traditional antibiotic classes were approved by the National Medical Products Administration (NMPA) in China in 2019 and 2021, respectively, and 18 antibacterial agents are in clinical development, with one under regulatory evaluation, five in phase-3, six in phase-2, and six in phase-1. Most of the clinical candidates are new analogs or mono-components of traditional antibacterial pharmacophore types, including two dual-acting hybrid antibiotics and a recombinant antibacterial protein. Overall, despite there being 17 antibacterial clinical candidates, our analysis indicates that there are still relatively few clinically differentiated antibacterial agents in stages of clinical development in China. Hopefully, Chinese pharmaceutical companies and institutions will develop more innovative and clinically differentiated candidates with good market potential in the future research and development (R&D) of original antibacterial drugs.
Antimicrobial resistance / New antibiotics / Clinical pipelines / WHO priority pathogens / National Mega-Project for Innovative Drugs
[[1]] |
|
[[2]] |
U.S. Mission Geneva. Antimicrobial resistance—no action today, no cure tomorrow [Internet]. Geneva: US Mission Geneva; 2011 Apr 5 [cited 2023 Jun 27]. Available from: https://geneva.usmission.gov/2011/04/05/antimicrobial-resistance-no-action-today-no-cure-tomorrow/#:∼:text=Anti-microbial%20resistance%20%E2%80%93%20or%20AR%20%E2%80%93%20is%20the,Cure%20Tomorrow%E2%80%9D%20to%20focus%20attention%20on%20the%20issue.
|
[[3]] |
WHO. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. Geneva: WHO; 2020 Jan 17 [cited 2023 Jun 27]. Available from: https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections.
|
[[4]] |
WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Geneva: WHO; 2017 Feb 27 [cited 2023 Jun 27]. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
|
[[5]] |
|
[[6]] |
|
[[7]] |
|
[[8]] |
|
[[9]] |
|
[[10]] |
|
[[11]] |
|
[[12]] |
|
[[13]] |
The State Council, People’s Republic of China. The national medium- and long-term program for science and technology development (2006-2020)—an outline [Internet]. Beijing: the State Council, People’s Republic of China; [cited 2023 Jun 27]. Available from: https://www.itu.int/en/ITU-D/Cybersecurity/Documents/National_Strategies_Repository/China_2006.pdf.
|
[[14]] |
Ministry of Science and Technology, People’s Republic of China. The major science and technology project of “major new drug creation” press conference [Internet]. Beijing: Ministry of Science and Technology, People’s Republic of China; 2019 Jul 31 [cited 2023 Jun 27]. Available from: https://www.most.gov.cn/xwzx/twzb/fbh19073101/.
|
[[15]] |
People’s Daily Online. The major science and technology project of “major new drug creation” ended [Internet]. Beijing: People’s Daily Online; 2021 Feb 2 [cited 2023 Jun 27]. Available from: https://www.gov.cn/xinwen/2021-02/02/content_5584285.htm.
|
[[16]] |
|
[[17]] |
WHO. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis [Internet]. Geneva: WHO; 2022 May 27 [cited 2023 Jun 27]. Available from: https://www.who.int/publications/i/item/9789240047655.
|
[[18]] |
|
[[19]] |
|
[[20]] |
|
[[21]] |
|
[[22]] |
|
[[23]] |
Beijing YouAn Hospital. The clinical study of carrimycin on treatment patients with COVID-19 [Internet]. Beijing: Beijing YouAn Hospital; 2020 Feb 27 [cited 2023 Jun 27]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04286503.
|
[[24]] |
|
[[25]] |
|
[[26]] |
|
[[27]] |
|
[[28]] |
MicuRx. Pipeline development: build global competitiveness in the field of anti-infection [Internet]. Shanghai: MicuRx; [cited 2023 Jun 27]. Available from: http://www.micurxchina.com/r-d-pipeline.
|
[[29]] |
|
[[30]] |
|
[[31]] |
|
[[32]] |
|
[[33]] |
|
[[34]] |
|
[[35]] |
|
[[36]] |
|
[[37]] |
|
[[38]] |
|
[[39]] |
|
[[40]] |
|
[[41]] |
|
[[42]] |
|
[[43]] |
|
[[44]] |
Shanghai Hi-tech Bioengineering Co., Ltd. Introduction to biotype skin and mucosal disinfectants [Internet]. Shanghai: Shanghai Hi-tech Bioengineering Co., Ltd.; [cited 2023 Jun 27]. Available from: http://www.hi-tech-bio.com/product/46/.
|
[[45]] |
|
[[46]] |
|
[[47]] |
|
[[48]] |
|
[[49]] |
TenNor Therapeutics. TNP-2092 IV: medical device associated bacterial biofilm infections [Internet]. Suzhou: TenNor Therapeutics; 2021 Dec 24 [cited 2023 Jun 27]. Available from: http://www.tennorx.com/cn/NewsD.html?id=389&page=3&type=1.
|
[[50]] |
TenNor Therapeutics. Clinical studies on the intra-articular local administration of TenNor Therapeutics’ TNP-2092 for prosthetic joint infections start [Internet]. Suzhou: TenNor Therapeutics; 2023 Sep 15 [cited 2024 Mar 11]. Available from: http://www.tennorx.com/cn/NewsD.html?id=455&page=1&type=1.
|
[[51]] |
|
[[52]] |
TenNor Therapeutics. Rifasutenizole for H. pylori received FDA QIDP designation [Internet]. Suzhou: TenNor Therapeutics; 2023 Apr 13 [cited 2023 Jun 27]. Available from: http://www.tennorx.com/cn/NewsD.html?id=376&page=1&type=1.
|
[[53]] |
|
[[54]] |
|
[[55]] |
db.yaozh.com [Internet]. Clinical trials in China. Chongqing: db.yaozh.com; [cited 2023 Jun 27]. Available from: https://db.yaozh.com/linchuangshiyan?comprehensivesearchcontent=%E8%82%BE%E7%82%8E.
|
[[56]] |
Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. Jincheng Jinsu’s litazolid (LT-01) dry suspension project completed its phase I clinical trial [Internet]. Zhongshan: Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd.; 2022 Nov 17 [cited 2023 Jun 27]. Available from: http://www.gdjcjs.com/newsInfo?newsid=25.
|
[[57]] |
|
[[58]] |
|
[[59]] |
|
[[60]] |
Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. Jincheng Jinsu Pharmaceutical: announcement on the ethical review approval of phase II clinical trials for litazolid dry suspension (LT-01) project [Internet]. Zhongshan: Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd.; 2023 Apr 18 [cited 2023 Jun 27]. Available from: https://finance.eastmoney.com/a/202304182695073310.html.
|
[[61]] |
|
[[62]] |
|
[[63]] |
|
[[64]] |
|
[[65]] |
|
[[66]] |
China PhIRDA. U.S.. FDA grants Shandong Hengli’s KBP-7072 as QIDP and fast track designations [Internet]. Beijing: China PhIRDA; 2016 Nov 23 [cited 2023 Jun 27]. Available from: http://www.phirda.com/artilce_14355.html.
|
[[67]] |
KBP Biosciences. KBP-7072 [Internet]. Singapore: KBP Bioscience; [cited 2023 Jun 27]. Available from: https://www.kbpbio.com/index.php?c=show&id=25.
|
[[68]] |
|
[[69]] |
|
[[70]] |
|
[[71]] |
|
[[72]] |
MicuRx. MicuRx Pharmaceuticals completed the first subject dosing of MRX-8 (a new drug against drug-resistant bacteria) in China [Internet]. Shanghai: MicuRx; 2022 Nov 19 [cited 2023 Jun 27]. Available from: https://www.micurx.com/1210.html#:∼:text=The%20ongoing%20Phase%201%20clinical%20trial%20in%20China,and%20is%20expected%20to%20be%20completed%20in%202023.
|
[[73]] |
|
[[74]] |
|
[[75]] |
|
[[76]] |
|
[[77]] |
|
[[78]] |
Jiangsu Aosaikang Pharmaceutical Co., Ltd. New drugs in development [Internet]. Nanjing: Jiangsu Aosaikang Pharmaceutical Co., Ltd.; [cited 2023 Jun 27]. Available from: https://www.ask-pharm.com/inside/4/87.html.
|
[[79]] |
PharmaSources. Monthly news review of PharmaSources (February)—R&D [Internet]. Shanghai: PharmaSources; 2023 Mar 13 [cited 2023 Jun 27]. Available from: https://www.pharmasources.com/news/news-review-of-pharmasources-75993.html.
|
[[80]] |
|
[[81]] |
|
[[82]] |
|
[[83]] |
|
[[84]] |
|
[[85]] |
|
[[86]] |
|
[[87]] |
|
[[88]] |
|
[[89]] |
|
[[90]] |
|
[[91]] |
TB Alliance, Institute of Materia Medica. TBI-223 [Internet]. New York City: The Working Group for New TB Drugs; [cited 2023 Jun 27]. Available from: https://www.newtbdrugs.org/pipeline/compound/tbi-223.
|
[[92]] |
|
[[93]] |
|
[[94]] |
|
[[95]] |
|
[[96]] |
|
[[97]] |
|
[[98]] |
|
[[99]] |
|
[[100]] |
|
[[101]] |
|
[[102]] |
|
[[103]] |
Sihuan Pharmaceutical Holdings Group Ltd. A study to assess efficacy and safety intravenous benapenem in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) [Internet]. Bethesda: National Library of Medicine; [cited 2023 Jun 27]. Available from: https://clinicaltrials.gov/study/NCT04505683?tab=history&a=1.
|
[[104]] |
Sihuan Pharmaceutical. Xuanzhu Biopharm entered into an exclusive licensing agreement with new Asia pharmaceutical for the development and commercialization of benapenem and plazomincin in the greater China territory [Internet]. Beijing: Sihuan Pharmaceutical; 2022 [cited 2023 Jun 27]. Available from: https://ir.sihuanpharm.com/en/investor-relations/latest-news/investor-news/xuanzhu-biopharm-entered-into-an-exclusive-licensing-agreement-with-new-asia-pharmaceutical-for-the-development-and-commercialization-of-benapenem-and-plazomincin-in-the-greater-china-territory/.
|
[[105]] |
|
[[106]] |
Ian Lloyd. The Pharma R&D Annual Review 2022: 30th Anniversary Infographic & Whitepaper [Internet]. London: Pharma Intelligence UK Limited; 2022 [cited 2023 Jun 27]. Available from: https://pages.pharmaintelligence.informa.com/rdreview.
|
[[107]] |
National Health Commission of the People’s Republic of China. Status report on antimicrobial administration and antimicrobial resistance in China. Beijing: Beijing Peking Union Medical College Press; 2022.
|
[[108]] |
|
[[109]] |
|
[[110]] |
|
[[111]] |
|
[[112]] |
|
[[113]] |
|
[[114]] |
|
[[115]] |
|
[[116]] |
|
[[117]] |
|
[[118]] |
|
[[119]] |
|
[[120]] |
|
/
〈 |
|
〉 |